Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel g

GlobeNewswireMay 1 20:00

Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22

Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22

BenzingaApr 29 23:48

J.P. Morgan Securities: Maintaining the Benitec Biopharma (BNTC.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $10.00 to $16.00.

J.P. Morgan Securities: Maintaining the Benitec Biopharma (BNTC.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $10.00 to $16.00.

Zhitong FinanceApr 23 00:20

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $10 to $16.

Analyst UpgradesApr 23 00:17

Benitec Biopharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 128.9% JMP Securities $10 → $16 Maintains Market Outperform 02/15/2024 43.06% JMP Securities $8

BenzingaApr 23 00:16

Benitec Biopharma's $40 Million Equity Financing Deal

TipRanksApr 19 18:13